Top-Rated Stocks NASDAQ:XENE Xenon Pharmaceuticals - XENE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $38.05 -1.14 (-2.91%) (As of 02/7/2023 10:14 AM ET) Add Compare Share Share Today's Range$37.97▼$39.2750-Day Range$35.67▼$39.4352-Week Range$24.94▼$41.39Volume12,851 shsAverage Volume377,686 shsMarket Capitalization$2.38 billionP/E RatioN/ADividend YieldN/APrice Target$50.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Xenon Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29.6% Upside$50.78 Price TargetShort InterestBearish5.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 4 Articles This WeekInsider TradingSelling Shares$138,005 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.10) to ($2.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector385th out of 1,027 stocksPharmaceutical Preparations Industry192nd out of 500 stocks 4.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.78, Xenon Pharmaceuticals has a forecasted upside of 29.6% from its current price of $39.19.Amount of Analyst CoverageXenon Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.80% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 1.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 3.1 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Xenon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,005.00 in company stock.Percentage Held by InsidersOnly 6.06% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions92.49% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.10) to ($2.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -19.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -19.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xenon Pharmaceuticals (NASDAQ:XENE) StockXenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.Read More Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $51.00January 31, 2023 | msn.comThe Latest Analyst Ratings for Xenon PharmaceuticalsFebruary 7, 2023 | PressReach (Ad)This Stock Could Rebound QuickIt's not often we see a stock with this much potential.January 20, 2023 | finance.yahoo.comInvestors in Xenon Pharmaceuticals (NASDAQ:XENE) have made a fantastic return of 965% over the past five yearsJanuary 9, 2023 | finance.yahoo.comXenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023December 23, 2022 | seekingalpha.comXenon Pharmaceuticals: Momentum Still Accelerating, Rate Buy (Technical Analysis)December 2, 2022 | finance.yahoo.comXenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)December 2, 2022 | finance.yahoo.comXenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)February 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 30, 2022 | finance.yahoo.comXenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022November 30, 2022 | finance.yahoo.comXenon Pharmaceuticals Stock Scores Rising Relative Strength UpgradeNovember 28, 2022 | markets.businessinsider.comWhere Xenon Pharmaceuticals Stands With AnalystsNovember 12, 2022 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%November 8, 2022 | seekingalpha.comXenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comXenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue EstimatesNovember 8, 2022 | msn.comEarnings Preview: Xenon PharmaceuticalsNovember 7, 2022 | finance.yahoo.comXenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate SecretaryNovember 3, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset SeizuresNovember 2, 2022 | apnews.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate UpdateNovember 1, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate UpdateOctober 6, 2022 | finance.yahoo.comAre Investors Undervaluing Xenon Pharmaceuticals Inc. (NASDAQ:XENE) By 32%?October 6, 2022 | finance.yahoo.comXenon Pharmaceuticals Inc. (XENE)September 21, 2022 | seekingalpha.comXENE Xenon Pharmaceuticals Inc.September 1, 2022 | finance.yahoo.comXenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare ConferenceAugust 29, 2022 | finance.yahoo.com10 Best Biotech Stocks To Buy NowAugust 29, 2022 | markets.businessinsider.comAnalyst Ratings for Xenon PharmaceuticalsAugust 18, 2022 | seekingalpha.comXenon Pharmaceuticals (XENE) Investor Presentation - SlideshowSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Company Calendar Last Earnings11/10/2021Today2/07/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees149Year FoundedN/APrice Target and Rating Average Stock Price Forecast$50.78 High Stock Price Forecast$60.00 Low Stock Price Forecast$45.00 Forecasted Upside/Downside+33.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,880,000.00 Net Margins-862.06% Pretax Margin-866.14% Return on Equity-17.31% Return on Assets-16.74% Debt Debt-to-Equity RatioN/A Current Ratio41.78 Quick Ratio41.78 Sales & Book Value Annual Sales$18.44 million Price / Sales129.05 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book3.62Miscellaneous Outstanding Shares62,540,000Free Float58,754,000Market Cap$2.38 billion OptionableOptionable Beta1.32 Key ExecutivesIan C. MortimerPresident, Chief Executive Officer & DirectorSherry AulinChief Financial OfficerSheila M. GrantExecutive VP-Research & Development OperationsChristopher KenneyChief Medical OfficerRobin SherringtonExecutive Vice President-Strategy & InnovationKey CompetitorsTG TherapeuticsNASDAQ:TGTXCorcept TherapeuticsNASDAQ:CORTVentyx BiosciencesNASDAQ:VTYXProthenaNASDAQ:PRTAAkero TherapeuticsNASDAQ:AKROView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 13,633 shares on 2/2/2023Ownership: 0.057%ProShare Advisors LLCBought 5,172 shares on 2/2/2023Ownership: 0.008%Simplex Trading LLCSold 1,900 shares on 2/2/2023Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Bought 2,772 shares on 2/1/2023Ownership: 0.015%New York State Common Retirement FundBought 650 shares on 1/30/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions XENE Stock - Frequently Asked Questions Should I buy or sell Xenon Pharmaceuticals stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares. View XENE analyst ratings or view top-rated stocks. What is Xenon Pharmaceuticals' stock price forecast for 2023? 12 equities research analysts have issued 1-year target prices for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $45.00 to $60.00. On average, they expect the company's share price to reach $50.78 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View analysts price targets for XENE or view top-rated stocks among Wall Street analysts. How have XENE shares performed in 2023? Xenon Pharmaceuticals' stock was trading at $39.43 at the start of the year. Since then, XENE stock has decreased by 0.6% and is now trading at $39.19. View the best growth stocks for 2023 here. When is Xenon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our XENE earnings forecast. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.08. The biopharmaceutical company had revenue of $8.12 million for the quarter, compared to analyst estimates of $7.76 million. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative trailing twelve-month return on equity of 17.31%. During the same quarter last year, the company earned ($0.25) EPS. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI). What is Xenon Pharmaceuticals' stock symbol? Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE." Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.15%), SG Americas Securities LLC (0.06%), New York State Common Retirement Fund (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), ProShare Advisors LLC (0.01%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xenon Pharmaceuticals' stock price today? One share of XENE stock can currently be purchased for approximately $39.19. How much money does Xenon Pharmaceuticals make? Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.45 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. How many employees does Xenon Pharmaceuticals have? The company employs 149 workers across the globe. How can I contact Xenon Pharmaceuticals? Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450. This page (NASDAQ:XENE) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.